Related Experiment Videos
PSA density (PSAD). Role in patient evaluation and management
E Seaman1, M Whang, C A Olsson
1Department of Urology, College of Physicians and Surgeons of Columbia University, New York, New York.
The Urologic Clinics of North America
|November 1, 1993
Summary
Prostate Specific Antigen (PSA) levels can be ambiguous for prostate cancer diagnosis. Prostate Specific Antigen Density (PSAD) offers crucial insights for intermediate PSA ranges, aiding in biopsy decisions and cancer likelihood assessment.
Area of Science:
- Urology
- Oncology
- Biomarkers
Background:
- Prostate Specific Antigen (PSA) is a key serum marker for prostate cancer.
- Current PSA testing has limitations in sensitivity and specificity, particularly for intermediate levels (4.1-10.0 ng/ml).
Purpose of the Study:
- To summarize the diagnostic and therapeutic utility of Prostate Specific Antigen Density (PSAD).
- To highlight PSAD's role in managing patients with intermediate PSA levels.
Main Methods:
- Review of existing literature on PSA and PSAD in prostate cancer.
- Analysis of PSAD's performance in differentiating benign conditions from prostate cancer.
Main Results:
- PSAD provides unique information beyond total PSA levels.
- PSAD aids in determining the necessity of prostate biopsy in equivocal cases.
- PSAD correlates with the probability of detecting prostate cancer upon biopsy.
Conclusions:
- PSAD is a valuable tool for refining prostate cancer diagnosis and management.
- Incorporating PSAD can improve clinical decision-making for patients with intermediate PSA values.
- Further research may elucidate optimal PSAD thresholds for clinical application.